Unknown

Dataset Information

0

Rivastigmine decreases brain damage in HIV patients with mild cognitive deficits.


ABSTRACT: Rivastigmine has been shown to improve cognition in HIV+ patients with minor neurocognitive disorders; however, the mechanisms underlying such beneficial effect are currently unknown. To assess whether rivastigmine therapy is associated with decreased brain inflammation and damage, we performed T1/T2* relaxometry and magnetization transfer imaging in 17 aviremic HIV+ patients with minor neurocognitive disorders enrolled on a crossed over randomized rivastigmine trial. Rivastigmine therapy was associated with changes in MRI metrics indicating a decrease in brain water content (i.e., edema reabsorption) and/or reduced demyelination/axonal damage. Furthermore, MRI changes correlated with cognitive improvement on rivastigmine therapy.

SUBMITTER: Perrotta G 

PROVIDER: S-EPMC5740253 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications


Rivastigmine has been shown to improve cognition in HIV+ patients with minor neurocognitive disorders; however, the mechanisms underlying such beneficial effect are currently unknown. To assess whether rivastigmine therapy is associated with decreased brain inflammation and damage, we performed T1/T2* relaxometry and magnetization transfer imaging in 17 aviremic HIV+ patients with minor neurocognitive disorders enrolled on a crossed over randomized rivastigmine trial. Rivastigmine therapy was as  ...[more]

Similar Datasets

| S-EPMC3589736 | biostudies-literature
| S-EPMC3272002 | biostudies-literature
| S-EPMC8155279 | biostudies-literature
| S-EPMC5576750 | biostudies-literature
| S-EPMC9712401 | biostudies-literature
| S-EPMC5908082 | biostudies-literature
| S-EPMC2769993 | biostudies-literature
| S-EPMC5561307 | biostudies-other
| S-EPMC5589177 | biostudies-literature
| S-EPMC6808357 | biostudies-literature